Richard J. "Rick" Barry is President, Chief Executive Officer, and Class II Director at Cassava Sciences, Inc. (SAVA), a biopharmaceutical company focused on Alzheimer's disease treatments.( He joined the Board in June 2021, served as Executive Chairman from July 2024, and was appointed CEO on September 6, 2024, following the resignation of prior leadership amid controversies.(

Barry, aged 66, holds a Bachelor of Arts from Pennsylvania State University and brings over 30 years of experience in investment management.( He was a founding member, Managing General Partner, and Portfolio Manager at Eastbourne Capital Management LLC (1999–2010), a large equity hedge fund with healthcare investments, and previously served as Portfolio Manager and Managing Director at Robertson Stephens Investment Management.( His career includes roles at Lazard Freres, Legg Mason, and Merrill Lynch, plus board service at Sarepta Therapeutics (since 2015, Chair of Nominating & Governance Committee), MiMedx Group (2019–2020), and Elcelyx Therapeutics (2013–2019).(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.